Obsidian Therapeutics
Obsidian Therapeutics is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to regulate the timing and level of protein function using FDA-approved small-molecule drugs.
Our lead product candidate, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL]) cell therapy armored with pharmacologically regulatable membrane-bound interleukin 15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and NSCLC by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. OBX-115 is designed to abrogate the need for concomitant interleukin 2 (IL2), a toxic and costly requirement for non-engineered TIL cell therapy. Eliminating IL2 is projected to expand patient eligibility by enabling treatment of patients who cannot tolerate or access IL2.
OBX-115 is being investigated in two ongoing clinical trials in advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) (NCT05470283 and NCT06060613).